SCHEMBL3853630

SCHEMBL3853630

CCCN(CCC)C(=O)c1ccnc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.48
EGFR P00533 2/20 0.47
ERBB2 P04626 2/20 0.47
MLYCD O95822 1/20 0.45
TP53 P04637 1/20 0.45
TSHR P16473 1/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
TAS1R3 Q7RTX0 2/20 0.40
TAS1R1 Q7RTX1 2/20 0.40
TAS1R2 Q8TE23 2/20 0.40
BACE1 P56817 1/20 0.40
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5156043 0.91 ALDH1A1 (0.49) HPGDEGFRERBB2MLYCDTP53
SCHEMBL9321390 0.87 ALDH1A1 (0.58) HPGDTSHRALDH1A1MAPTL3MBTL1
SCHEMBL16569986 0.83 ALDH1A1 (0.53) HPGDEGFRERBB2MLYCDTP53
SCHEMBL3857943 0.80 ALDH1A1 (0.57) HPGDEGFRERBB2MLYCDTP53
SCHEMBL20519836 0.79 ALDH1A1 (0.45) HPGDTSHRALDH1A1MAPTL3MBTL1
SCHEMBL4926597 0.78 TAS1R3 (0.44) HPGDALDH1A1MAPTL3MBTL1TAS1R3
SCHEMBL11619832 0.77 HPGD (0.44) HPGDEGFRERBB2MLYCDTP53
SCHEMBL9540613 0.76 MLYCD (0.57) HPGDEGFRERBB2MLYCDTP53
SCHEMBL3854935 0.75 ALDH1A1 (0.77) HPGDEGFRERBB2MLYCDTP53
SCHEMBL5860112 0.75 TAS1R3 (0.44) HPGDALDH1A1MAPTL3MBTL1TAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618978-B2 Amides as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-11-17 US disclosed
US-7585885-B2 Pyrrolidine derivatives useful as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-09-08 US disclosed
US-20070225372-A1 Amides as Bace Inhibitors ELI LILLY AND COMPANY 2007-09-27 US disclosed
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS ELI LILLY AND COMPANY 2007-09-13 US disclosed
EP-1740575-A2 PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2007-01-10 EP disclosed
EP-1740573-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2007-01-10 EP disclosed
WO-2005108391-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2005-11-17 WO disclosed
WO-2005108358-A2 PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225372-A1 Amides as Bace Inhibitors BACE2, BACE1, APP HPGD 2737/4885EGFR 110/4885ERBB2 167/4885
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS BACE1, BACE2, PSEN1 HPGD 672/4885EGFR 1101/4885ERBB2 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.